Yiquan Xu

机构：Fujian Medical University, Fujian Provincial Cancer Hospital · ORCID：0000-0003-4189-9692

发表论文 59 篇 · 总被引 542 次 · h-index 11

代表论文

• 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study (2024 · Immuno-Oncology Technology · 被引 14)
• CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation (2024 · Cell Death and Disease · 被引 11)
• Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer (2023 · Journal of Neuro-Oncology · 被引 10)
• Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis (2023 · Journal of Neuro-Oncology · 被引 10)
• Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study (2023 · BMC Cancer · 被引 7)
• Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer (2023 · Thoracic Cancer · 被引 5)